The estrogen receptor alpha (ERa) signaling plays an essential role in breast cancer progression and endocrine therapy. Mitogen-activated protein kinase (MAPK/ Erk1/2) has been implicated in ligand-independent activation of ER, resulting in the cross-talk between growth factor and ER mediated signaling. In this study, we examined the eect of the cross-talk on estradiol (E 2 )-mediated signaling, tumor growth and its eect on anti-estrogen therapy. Our ®ndings demonstrate that expression of constitutively activated mitogen activated kinase kinase (MEK1), an immediate upstream activator of MAPK in estrogen receptor positive MCF-7 breast cancer cells (MEK/MCF-7), showed an increase in ERadriven transcriptional activation. In MEK/MCF-7 cells maximal transactivation levels were achieved in response to treatment with much lower E 2 concentrations (10 710 M E 2 ) when compared to MCF-7 control cells (10 78 M E 2 ). Furthermore, we have seen an increased association between ERa and its nuclear coactivators AIB1 or TIF-2, in MEK/MCF-7 cells relative to those seen in MCF-7 control cells. In addition, in vivo studies show that MEK/ MCF-7 cell tumors are *threefold larger than those of MCF-7 cell, in the presence of E 2 . Immunohistochemical staining demonstrates that progesterone receptor (PR) and pS2, two E 2 -regulated gene products, are signi®-cantly increased in MEK/MCF-7 cell tumors compared to those of MCF-7 control tumors, suggesting that activation of ERa by MAPK enhances the expression of E 2 -regulated genes and accelerates tumor growth. Remarkably, the antiestrogens tamoxifen and ICI 182,780, were shown both in vitro and in vivo studies to eciently antagonize the stimulatory eects of E 2 on ER regulated transactivation and tumor growth in MEK/ MCF-7 as well as MCF-7 cell lines. Taken together, these data suggest that MAPK/ER cross-talk enhances ERa-mediated signaling and accelerates E 2 -dependent tumor growth without diminishing sensitivity to the inhibitory eects of anti-estrogens.
Introduction
The biological activity of E 2 is mediated by two closely related members of the nuclear receptor family of ligandactivated transcription factors, estrogen receptor alpha (ERa) and estrogen receptor beta (ERb). Cloning of the cDNAs encoding the ERa and comparison with ER from other species have been used to divide ERa into six regions, A to F, on the basis of sequence homology and functional activity (Krust et al., 1986; Kumar et al., 1986) . Numerous studies have shown that region C encodes the DNA binding domain (DBD), and region E contains the hormone/ligand binding domain (LBD) (Green and Chambon, 1988; Kumar et al., 1986; O'Malley et al., 1991) . ERa contains both hormoneindependent and hormone-inducible transactivation functions (AF-1 and AF-2), located in the N-terminal A/B domain and in the LBD, respectively (Danielian et al., 1992; Kumar et al., 1986; Metzger et al., 1995; Tora et al., 1988) . AF-1 and AF-2 can function independently or synergistically to activate transcription and promote signaling depending on the cell and promoter context (Kumar et al., , 1987 Lees et al., 1989) . E 2 binds ER and induces conformational changes, which lead to receptor dimerization, high anity binding to estrogen-responsive elements (EREs), and subsequent gene expression. Hormone-induced activation of ERa also promotes intra-molecular conformational changes that allow an interaction between AF-1 and AF-2; which results in the recruitment of coactivator proteins (Xu et al., 1999) . Hormone independent activation of ERa by growth factors leads to phosphorylation of Ser 118 located within AF-1 (Ali et al., 1993; Joel et al., 1995) . The ®ve amino acids located encompassing Ser 118 (PQLSP) are conserved among ER of several vertebrate species (human, mouse, rat, chick, xenopus and trout) and correspond to the consensus phosphorylation site for mitogen activated protein kinase (MAPK) (Gonzalez et al., 1991) . Previous work has shown that growth factor pathways, including IGF-1, EGF, and TGFa, can activate the estrogen receptor (Kato et al., 1998; Yee and Lee, 2000) . Studies using deletion mutants of ERa have shown that AF-1, which is not required for activation by E 2 , is indispensable to EGF or IGF-1 (El-Tanani and Green, 1997; Ignar-Trowbridge et al., 1993) , thus implicating AF-1 in the mediation of ligand-independent activation of ER. Furthermore, these studies showed that deletion mutants of ERa lacking AF-2 could be activated by EGF and IGF-1, but were unresponsive to E 2 . In conjunction with earlier data implicating AF-1 in ligand-independent action, Ser 118 , within the ERa AF-1 region, was found to be a target for phosphorylation by MAPK (Bunone et al., 1996; Kato et al., 1995) . Since many growth factor pathways converge on MAPK, it is thought that MAPK-mediated phosphorylation of AF-1 represents a mechanism whereby the activity of ERa can be enhanced by growth factor receptor activation.
In ER`knock-out' (ERKO) mice, both estrogen and EGF stimulation of uterine growth is disrupted (Curtis et al., 1996) . This suggests that ER may mediate the transcription of target genes by integrating dierent signals from growth factor-activated kinases and the binding of steroid hormones. However, the importance of growth factor induction of ER transcriptional activity in normal physiology and in tumor progression is essentially unknown. We have investigated these key issues by using MEK/MCF-7 cells that express a constitutively activated MEK mutant; which results in enhanced activation of MAPK. Our results suggest that the induction of ERa activity by MAPK enhances ER signaling and promotes tumor growth in the presence of E 2 . These tumors were still responsive to anti-estrogen therapy.
Results

Constitutively activated MEK induces ligand-independent ER activation and enhances transcriptional activity in vitro
Previous studies showed that MAPK mediates the estrogenic functions of EGF and IGF1 (Ignar-Trowbridge et al., 1993 . In order to establish steroid independent activation in our system, we transfected MCF-7 cells with constitutively activated MEK cDNA and developed stable cell lines (MEK/MCF-7 cells) ( Figure 1a) . Recently Joel et al. (1998) showed that phosphorylation of Ser 118 on ERa reduced the electrophoretic mobility of the receptor. Using this same mobility shift assay, we compared the ER migration patterns from MEK/MCF-7 clones with MCF-7 control cell line. As shown in Figure 1b , there was a reduction in the electrophoretic mobility of ER derived from untreated MEK/MCF-7 cells with activated MAPK, relative to that of the parental cell ER. We con®rm that MAPK induces ERa phosphorylation at Ser 118 by Western immunoblotting and immunostaining using phospho-ERa (Ser118) monoclonal antibody (Cell Signaling, Beverly, MA, USA) ( Figure 1c) .
To evaluate the eects of activated MAPK on ERtransactivation and ligand responsiveness, we performed transient transfection assays. MCF-7 and MEK/MCF-7 cells were co-transfected with ERE-TK-Luc or TK-Luc and the internal control vector, pRL, and evaluated for changes in the levels of basal (untreated) and E 2 -induced reporter activity. The basal transcriptional activity levels (obtained in the absence of E2) in MEK/MCF-7 cells were found to be *threefold higher than those in parental MCF-7 cells (Figure 1c ). This suggests that cross-talk between MAPK and ER enhances EREreporter activity in a ligand-independent manner. Treatment with 10
78 M E 2 resulted in a *14 to *15-fold increase in ERE-reporter activity in MEK/MCF-7 cells relative to basal levels in untreated cells, whereas only a *5 ± 6-fold increase in reporter activity was observed in E 2 -treated MCF-7 cells (Figure 2 ). This represents a *3-fold increase in reporter activity when compared to control MCF-7 cells in response to E 2 -stimulation. Anti-estrogens (4-hydroxytamoxifen or ICI 182,780) and anti-MEK inhibitors (PD 98059 or UO126) inhibited E 2 -induced expression of the ERE-reporter gene activity in both MEK/MCF-7 and control cells (Figure 2 ). In co-treatment assays, using both antiestrogens and MEK inhibitors in combination, ERE reporter activity induced by E 2 was completely abolished. To rule out a role for non-genomic E 2 -mediated signaling we treated MEK/MCF-7 and MCF-7 cells with membrane impermeable BSA conjugated E 2 (BSA-E 2 ). MEK/MCF-7 and MCF-7 cells treated with BSA-E 2 did not induce ERE-activation at 15 min, 1, 2, 4 and 24 h time points (data not shown). These results show that MAPK-induced phosphorylation at Ser118 of ER increases ERE reporter activity in the presence and absence of E 2 .
Steroid-independent activation of ER lowers E 2 requirement and enhances coactivator recruitment to ER To determine if cross-talk between MAPK and ER alters the E 2 requirement for optimal stimulation, MEK/MCF-7 and MCF-7 control cells were treated with dierent concentrations of E 2 (10 76 to 10
and E 2 activated ERE-luciferase transcriptional activity was determined. MEK/MCF-7 cells showed optimal activation of ERE-luciferase activity at 10 710 M E 2 -stimulation and in contrast MCF-7 control cells showed maximum activity at 10
78 M E 2 -stimulation ( Figure 3 ). This data shows that MAPK and ER crosstalk reduces E 2 requirement for optimal activation of ERE-reporter gene.
It has been proposed that E 2 signaling is mediated by recruiting transcriptional coactivators to the ligandbinding domain of the ER (Xu et al., 1999) . Hence, we compared the interaction between ER and the coactivators such as AIB1 and TIF-2 in both MEK/MCF-7 and MCF-7 control cells in the presence and absence of E 2 . To rule out if transfection of MEK-transfection leads to changes in the expression of ER or coactivators we estimated the levels of ER, AIB1 and TIF-2 in both the cell lines by semi-quantitative RT ± PCR. Relative to b-actin, a house keeping gene, the only dierence observed was in the levels of ER which were reduced in MEK/ MCF-7 cells when compared to control MCF-7 ER in absence of E 2 . However coactivator levels remained unchanged in both the cell lines in the presence and absence of E 2 ( Figure 4a ). One of the reasons for reduced ER levels in MEK/MCF-7 cells when compared to MCF-7 control cells may be due to ligand-independent activation of ER in MEK/MCF-7 cells. To further con®rm the above data MEK/MCF-7 and MCF-7 cells were stimulated with E 2 and ER levels were estimated. As expected, E 2 treatment decreased the steady state levels of ERa expression in both the cell lines, consistent with previously published data showing that ER activation resulted in nuclear translocation and subsequent ubiquitination (Anderson et al., 1998; Nawaz et al., 1999) . Hormone-induced activation of ERa promotes intramolecular conformational changes that allow an interaction between AF-1 and AF-2; which results in the recruitment of coactivator proteins (O'Malley et al., 1991; Xu et al., 1999) . In order to evaluate the potential for cross-talk mediated enhancement in ER-coactivator interactions and ER signaling, we used immunoblotting to assess these interactions in MEK/MCF-7 and MCF-7 control cells in the presence and absence of E 2 . In MEK/ MCF-7 cells ER/AIB1 and ER/TIF-2 interactions are higher compared to control MCF-7 cells in absence of E 2 suggesting that MAPK and ER cross-talk leads to activation of ER and recruitment of coactivators. Addition of E 2 further enhances ER/AIB1 and ER/ TIF-2 interactions in both cell lines (Figure 4b ). These results are consistent with our hypothesis that cross-talk between MAPK and ER enhances E 2 mediated signaling.
Ligand-independent activation of the ER lowers E 2 requirement for tumor growth in vivo Finally, we tested whether the transcriptional data seen in vitro correlates with tumor cell growth in vivo. We injected the MEK/MCF-7 and control MCF-7 cells subcutaneously on either side of an ovariectomized The arrows indicate the Ser118 phosphorylated ERa (Green) and the blue is DAPI nuclear staining. ERa Ser118 was also con®rmed by Western blotting analysis using phosphoER-Ser118 monoclonal Ab (Cell Signaling, MA, USA). (d) Activated MAPK enhances ER-driven reporter activity in MEK/MCF-7 cells in the presence and absence of E 2 . MCF-7 cells and MEK/MCF-7 clones 1, 3, 12 were transiently transfected with 1.0 mg/well of either EREtkLuc (the ERE-containing reporter plasmid) or tkLuc (the corresponding empty reporter vector with no EREs) and cotransfected with 0.1 mg/well of pRL (an internal reporter plasmid to control for transfection eciency). The cells were treated with E 2 (10 78 M) or ethanol vehicle control (0.1%) for 48 h and then harvested. Cell extracts were prepared and analysed for luciferase activity, as described in Materials and methods. The magnitude of activation obtained from tkLuc-transfected cell extracts (as determined after normalization to pRL activity) was used to calculate reporter activity. Transactivation is reported as the foldinduction relative to the basal level of luciferase activity in cells transfected with the empty tkLuc reporter vector, which is arbitrarily set at 1.0-fold. Note that values for tkLuc activity did not dier substantially between cell lines or in response to treatment with ligands (not shown) SCID mouse in the presence or absence of b-estradiol (0.72 mgs/pellet, 60 day slow release pellet). Animals were scored for tumor formation initially after 1 month and then twice weekly for another 2 weeks. Data from two dierent clones and three separate experiments have shown that estradiol supplementation accelerates growth of MEK/MCF-7 tumors (6050+430, mean+s.e.m.) by *threefold relative to control MCF-7 tumors (2041+140, mean+s.e.m.) (Figure 5a ). In contrast, in mice that were not supplemented with E 2 , MCF-7 cells were unable to form tumors, while MEK/MCF-7 cells formed small palpable tumors. One of the reasons for the MEK/MCF-7 ability to form palpable tumors may be ligand-independent activation of ER due to crosstalk between MAPK and ER. To further demonstrate that MAPK induced activation of ER lowers E 2 -requirement for tumor cell growth, MEK/MCF-7 and MCF-7 cells were injected subcutaneously on either side of the same non-ovariectomized mice. It was previously shown that non-ovariectomized mice have *26 pg/ml of circulating E 2 (Laidlaw et al., 1995) , which compares to the low levels found in postmenopausal women (Anderson et al., 1998) . In these mice, MEK/MCF-7 cells formed tumors that are 8 ± 9-fold larger (697+106, mean+s.e.) when compared to control cells (57+14, mean+s.e.m.) (Figure 5b ). Immunohistochemical staining of the tumors showed a signi®cant increase in E 2 -induced genes such as progesterone receptor (PR) and pS2 in MEK/MCF-7 tumors when compared to control MCF-7 tumors ( Figure 6 ). This data is consistent with our hypothesis that MAPK induced ER activation enhances ERmediated signaling and tumor cell growth. To evaluate the eect of anti-estrogens on tumor cell growth, we treated the mice with Tamoxifen and ICI-182,780 after establishing E 2 -induced tumors. Both MEK/MCF-7 and control MCF-7 tumor cells were inhibited by antiestrogens, tamoxifen and ICI 182,780 (Figure 5a ). This data demonstrates that MAPK-induced ER activation lowers E 2 requirement for tumor cell growth and these tumors are still sensitive to anti-estrogen therapy.
Discussion
It is well established that peptide growth factor signaling pathways can activate the estrogen receptor in absence of its ligand through phosphorylation of ER by MAPK (Kato et al., 1998; Yee and Lee, 2000) . However, the role of MAPK induced ER activation on ER-mediated signaling, tumor cell growth, and anti- , or U0126 (10 mM) individually or in combination, harvested and assayed for luciferase activity. The addition of E 2 signi®cantly enhanced ERE-reporter activity while antiestrogens blocked E 2 -induced transactivation. MEK inhibitors, PD 98059 or U0126, inhibited E 2 -induced ERE activity in both the MEK/MCF-7 clones and MCF-7 control cell lines. EREtkLuc activity was completely abolished by cotreatment with antiestrogens and MEK inhibitors. Luciferase relative light units were normalized to the pRL relative light units and used to calculate fold induction based on a comparison to the activity obtained from transfections using the tkLuc vector which lacks the ERE insert (set at 1.0-fold), as described in Figure 1 . The data shown here are from three separate experiments, represented as the means+s.e.m. Figure 3 Cross-talk between MAPK and ER lowers E 2 concentration required for optimal stimulation in MEK/MCF-7 cells. MEK/MCF-7 and MCF-7 control cells were transiently cotransfected with the EREtkLuc reporter or the empty tkLuc vector and pRL, an internal control plasmid, as described in Materials and methods. The cells were exposed to medium containing E 2 concentrations ranging from 10 712 to 10 77 M for 48 h, harvested and assayed for luciferase activity. MEK/MCF-7 cells showed optimal activity when stimulated with 10
710 M E 2 in comparison to MCF-7 control cells which required 10
78 M E 2 for optimal activation. For clarity, three separate concentration points, 10
78
, 10 710 and 10 712 M E 2 , are shown. Luciferase relative light units were normalized to the pRL relative light units and used to calculate fold induction based on a comparison to the activity obtained from transfections using the tkLuc vector which lacks the ERE insert (set at 1.0-fold). The data shown here are from three separate experiments, represented as the means+s.e.m. estrogen therapy is poorly understood. In this report, we demonstrated that MAPK induced ERa activation (cross-talk) in MEK/MCF-7 cells leads to estrogenindependent ER phosphorylation and ERE-reporter transcriptional activity. ER transcriptional activity can also be enhanced by non-genomic E 2 -mediated signaling in some cell lines (Castoria et al., 1999; Song et al., 2002) . When MCF-7/MEK and MCF-7 control cells were treated with membrane impermeable BSA conjugated E 2 , no ERE transcriptional activity was detected ruling out the possible non-genomic eects of E 2 in these cells. In addition we have shown that ligand-independent activation of ERa lowers E 2 requirement for optimal transcriptional activity. Consistent with these observations, previous studies have shown that MAPK phosphorylates Ser118 of ERa leading to enhanced transcriptional activity (El-Tanani and Green, 1997; Kato et al., 1995) .
Current models of ER action suggests that it modulates the rate of transcription through interactions with the basal transcription machinery, via the recruitment of a variety of cofactors. In our study, MEK/MCF-7 cells showed a signi®cant increase in recruitment of coactivators such as AIB1 and TIF-2 to ER, when compared to control cells in absence of E 2 -stimulation. In addition, E 2 -stimulation signi®cantly enhanced AIB1 and TIF-2 coactivator recruitment to ER in both the cell lines. The molecular mechanism by which MAPK enhances interactions between ER and coactivator is not fully understood. However, recent studies suggest that SRC-1, TIF-2 and AIB-1 can be phosphorylated by MAPK in addition to ER (Font de Rowan et al., 2000) , an event shown to enhance transcriptional activity. One of the reasons for enhanced ER signaling and tumor cell growth seen in our study may be due to the ability of MAPK to phosphorylate coactivators in addition to ER. Consistent with the above in vitro data, MCF-7/ MEK cells formed *threefold larger tumors when compared to control MCF-7 cells in the presence of E 2 in vivo. Immunohistochemical staining of the tumors showed a signi®cant increase in E 2 -induced genes such as PR and PS2 in MEK/MCF-7 tumors when compared to control MCF-7 tumors. This shows that cross-talk enhances estrogen-responsive gene expression and tumor cell growth in mice. Since MEK/MCF-7 cells showed lower E 2 -requirement for optimal transcriptional activity in vitro, we looked at tumor growth of MEK/MCF-7 cells in non-ovariectomized SCID mice. These mice have lower levels of circulating E 2 (*26 pg/ml) when compared to the mice supplemented with estrogen pellet (*124 pg/ml) (Laidlaw et al., 1995) . Even at the low E 2 levels, the MEK/MCF-7 cells formed 8 ± 9-fold larger tumors than control MCF-7 cells. This data supports our hypothesis that MAPK induced ERa activation lowers E 2 -requirement for optimal ER-signaling and tumor growth. MCF-7 control cells are unable to form tumors, yet MEK/ MCF-7 cells can form palpable tumors in absence of E 2 in ovariectomized SCID mouse. This suggests that MAPK-induced ER activation (cross-talk) was sucient for tumor formation, but could not sustain further tumor growth without E 2 -stimulation in MCF-7 breast cell lines even when the tumors were allowed to grow for 12 weeks (data not shown). However, there is data showing that transfection of constitutively active MEK confers tumorigenic and metastatic potential in NIH3T3 cells (Mansour et al., 1994; Welch et al., 2000) suggesting the possibility that activated MEK may in¯uence the behavior based on cell type.
Our data shows that anti-estrogens tamoxifen and ICI 182,780 signi®cantly inhibited both MEK/MCF-7 and MCF-7 control tumors in vivo. However, recent studies from other groups indicate that HER-2 induced MAPK and ERa activation leads to tamoxifen resistance (Benz et al., 1992; Kurokawa et al., 2000) . One of the reasons for this discrepancy may be due to the fact that signal transduction through the ErbB family of receptors leads to the activation of both AKT and the MAPK, among other signaling molecules (Tari and Lopez-Berestein, 2000) . This leads to the possibility that HER-2 activation can phosphorylates ERa at Ser-167 by AKT and Ser-118 by MAPK leading to tumor cell growth and anti-estrogen resistance (Campbell et al., 2001 ). In addition, it was recently shown that activated AKT-2 phosphorylates ERa at Ser-167 in vitro and in vivo. Furthermore, this AKT-2 induced ERa activity was not inhibited by tamoxifen but was completely abolished by ICI 164,384, implicating that AKT-2-activated ERa contributes to tamoxifen resistance (Sun et al., 2001) . Additional studies with mutants of ERa at Ser-118 and Ser-167 may be are essential to distinguish between these possibilities. There is clinical evidence indicating that patients with poor response to anti-hormonal therapy have associated MAPK overexpression (Gee et Figure 6 Cross-talk enhances ER induced gene expression: Immunohistochemical staining of the tumors show a signi®cant increase in E 2 -induced genes such as PR and PS2 in MEK/MCF-7 tumors when compared to control MCF-7 tumors. This data is consistent with our hypothesis that cross-talk sensitizes cells to E 2 -stimulation al., 2001; Sivaraman et al., 1997) . However, our data suggest that more careful evaluation has to be done to see whether other proteins, such as Akt, are activated in addition to MAPK in tamoxifen resistant tumors.
In summary, we have shown that MAPK-induced ER activation leads to lower requirement of E 2 and it also enhanced interaction between ER and coactivators such as AIB-1 and TIF-2 leading to enhanced ER signaling and tumor growth. Anti-estrogens such as tamoxifen and ICI 182,780 inhibited MEK/MCF-7 tumor growth. This suggests that MAPK induced ERa activation is sucient to enhance E2-mediated signaling, but not to induce the anti-estrogen resistant phenotype in vitro and in vivo. This study provides an insight into mechanisms by which MAPK and estrogen receptor cross-talk in¯uences E 2 -mediated signaling, tumor growth and tamoxifen sensitivity in breast cancer.
Materials and methods
Materials
DMEM, phenol red-free DMEM, recombinant human insulin, and fetal bovine serum were from GIBCO ± BRL. Charcoal-treated fetal bovine serum was from Cocalico Biologicals (PA, USA). The 17 b-estradiol (E 2 ) and 4-hydroxytamoxifen (Tam) from (Sigma), ICI 182,780 from Tocris (Ballwin, MO, USA). PD 98059 was obtained from Calbiochem (San Diego, CA, USA). The 17 b-estradiol pellets (0.72 mg pellet, 60 day release) from Innovative Research of America (Sarasota, FL, USA). Phospho-MAPK antibody from New England Biolabs (MA, USA). Anti-MAPK antibody from Zymed Laboratories (CA, USA). ER antibody from DAKO (Carpinteria, CA, USA) and NeoMarkers, PR and pS2 antibodies from NeoMarkers (Freemont, CA, USA). Human breast cancer MCF-7 cells were purchased from American Type Culture Collection. The cells were grown in DMEM supplemented with 10 ng/ml insulin, 5% fetal calf serum and antibiotics (penicillin/streptomycin).
Transfection and establishment of stable cell lines
Constitutively activated MAP kinase Kinase (MEK) cDNA was kindly provided by Dr Ahn (University of Colorado, Boulder, CO, USA). In brief, constitutively activated MEK was constructed by combining a deletion of a helix encompassing residues 32 to 51 with the substitution of glutamic or aspartic acid for Ser 218 and Ser 222 (Mansour et al., 1994) . For establishment of clonal cell lines, cells were grown to *60 ± 70% con¯uency in complete medium, harvested by trypsinizing and suspending in complete medium at 1610 5 cells/ml. After mix 0.4 ml of cells with DNA (1 mg of pMCL HA-tagged MEK/CMV promoter) and electroporating in a Bio-Rad Gene Pulsar at 950 mF and 0.22 kV/cm (t=20 ± 30 ms). Cells were allowed to stand at room temperature for 10 min before adding 5 ml of complete medium and incubating for 48 h. Cells were then split and grown in the presence of hygromycin to isolate at least 20 clonal hygromycin-resistant cell lines. Immunoblot analysis and kinase assay was done to select the constitutively activated MEK expressing (MEK/MCF-7 cell) and control MCF-7 cell lines.
The immunohistochemistry protocol
Cells were plated on coverslips in 24 well dish and grown in 0.05% BSA/DMEM phenol red free for 48 h. The cells were washed with PBS and were ®xed with 100% Methanol for 5 min. The ®xed cells were blocked using 5%BSA/PBS solution for 30 min, and incubated overnight with primary ER-Ser118 Ab diluted (1 : 50) in Tris buer saline (50 mM Tris-HCl (pH 7.4), 150 mM NaCl) (Cell Signaling, MA, USA). Cells were incubated with Alexa 488 goat anti-mouse Ab ann DAPI (Molecular Probes, OR, USA) for 1 h (1 : 100). The slips were mounted on slides with Slow Fade reagent (Molecular Probes, OR, USA) and images were captured using¯uorescence microscopy.
Immunoprecipitation and immunoblot analysis
Immunoblots were performed as described previously (Kondapaka et al., 1997) by standard methods on crude protein extracts obtained from 5610 6 cells untreated or treated. Cell extracts containing 50 mg of total protein per sample (determined by using Sigma protein assay) were analysed by SDS ± PAGE using 12% polyacrylamide gels or as indicated. Proteins on the gels were then transferred to nitrocellulose membranes and probed with antibodies speci®c for p44/p42 MAPK (rabbit polyclonal antibodies; Zymed Laboratories) or anti phospho-MAPK (New England Biolabs) as speci®c primary antibody. Filters were then washed and incubated with speci®c secondary peroxidase-conjugated antibodies and stained with enhanced chemiluminescence reagents (Amersham, Piscataway, NJ, USA). To determine an ER/AIB1 or ER/TIF2 association, 1 mg of cell lysates were ®rst precipitated with the AIB1 antibody or TIF-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (2.0 mg/mg protein) and protein G-Sepharose (Sigma, St Louis, MO, USA), followed by immunoblot analysis for ER and/or coactivators (NeoMarkers, Freemont, CA, USA).
ER dependent reporter transcriptional activity
Both cell lines were propagated in DMEM containing 5% dextran coated charcoal (DCC)-stripped fetal bovine serum (FBS) for 5 days before the onset of experiments. For experiments, the cells were seeded into 24-well plates at a density of 1610 5 cells/well and allowed to reach *60% con¯uence. Using Superfect (Qiagen) according to the manufacturer's instructions, the cells were then transfected with 1.0 mg/well of either the estrogen responsive reporter, ERE-tkLuc, containing a Vitellogenin A2-derived ERE as described elsewhere (Fan et al., 1996; Henttu et al., 1997) or the corresponding empty vector, tkLuc (with no ERE) along with 0.1 mg/well of the internal control plasmid pRL, used to correct for transfection eciency. After 4 h, the transfected cells were washed and then incubated in fresh DMEM medium containing 5% DCC-stripped FBS plus 0.05% BSA, supplemented with E2 (at the indicated concentrations), ICI 182,780 (10 76 M), 4-hydroxytamoxifen (10 77 M), PD 98059 (40 mM), and/or U0126 (10 mM) or 0.1% ethanol vehicle alone for 48 h. The cells were harvested and the cell extracts were assayed for luciferase activities using the dual-luciferase reporter system (Promega, Madison, WI, USA) according to the protocol speci®ed by the manufacturer. The magnitude of activation in tkLuctransfected cells was determined after normalization to the activity of pRL and then taken as 1.0 fold. This value was used to calculate the relative (fold) change in transcriptional activities of ERE-tkLuc-transfected cells, after normalization to pRL activity. There were no substantial dierences in the activity of the tkLuc vector between cell lines or in response to treatment with ligand or MAPK inhibitors. All data have been normalized as the ratio of raw light units to pRL units corrected for pRL activity, and are shown as the means+s.e. from three separate experiments (performed in triplicate).
RT ± PCR technique
Total cellular RNA was extracted from MEK/MCF-7 and control cells with TRIzol RNA extraction kit (Life Technology, Inc, Gaithersburg, MD, USA), according to the manufacturer's recommendation. The sequences of the primer/probe sets used for each analysis are as follows: ER: F, 5'-AGACATGAGAGCTGCCAACC-3'; R, 5'-GCCAGG-CACATTCTAGAAGG-3'; AIB1: F, 5'-CGTCCTCCATA-TAACCGAGC-3'; R, 5'-TCATAGGTTCCATTCTGCCG-3'; TIF-2: F, 5'-TAATGCACAGATGCTGGCC-3'; R, 5'-TCTGTGTATGTGCCATTCGG-3', b-actin: F, 5'-TGAC-GGGGTCACCCACACTGTGCCCATCTA-3'; R, 5'-CTAG-AAGCATTTGCGGTGGACGATGGAGGG-3'. Where F and R are the forward and reverse primers, respectively. bactin was used as a housekeeping gene. RT ± PCR reactions are done using superscript one step RT ± PCR kit (Life Technology, Inc, Gaithersburg, MD, USA) according to the manufacturer's recommendation.
Tumorigenesis in Scid-beige mouse
MCF-7 cells (1610 6 cells/mouse) control (vector alone) or MEK/MCF-7 cells were suspended in matrigel and injected subcutaneous (s.c.) on either side of the mouse in Scid-beige, ovariectomized mice (Taconic Farms, Germantown, NY, USA). The estrogen treated mice received implantation of E 2 pellets (17b-estradiol 7 0.72 mg/biodegradable carrier-binder pellet) subcutaneously at the time of cell inoculation. Antiestrogen Tamoxifen (5 mg/biodegradable carrier-binder pellet) or ICI-182,780 (5 mg/biodegradable carrier-binder pellet) were implanted after 30 days. All pellets were 60 day biodegradable slow release pellets obtained from Innovative Research of America (Sarasota, FL, USA). Five animals were included in each group in three sets of independent experiments. We used two dierent MEK/MCF-7 clones (clones 1 and 12) in this study to eliminate the possible clonal variations. Tumor growth was monitored by twice weekly measurement of the length (a) and width (b) of tumor and volumes calculated as (a6b 2 )/2.
